Literature DB >> 10845829

Glomerular filtration rate in severely overweight normotensive humans.

P Anastasio1, L Spitali, A Frangiosa, D Molino, D Stellato, E Cirillo, R M Pollastro, L Capodicasa, J Sepe, P Federico, N Gaspare De Santo.   

Abstract

The study examined whether indexing glomerular filtration rate (GFR) for body surface area is appropriate for people who are severely overweight. Twenty normotensive adult men who were severely overweight but without microalbuminuria were enrolled into this study. The control group consisted of 20 healthy subjects matched for age, sex, and height. GFR was determined by measuring insulin with the continuous-infusion method. The clearance of endogenous creatinine was also measured after two daily urine collections. Renal plasma flow (RPF) was measured by p-aminohippurate clearance using the continuous-infusion method. Lean body weight was measured by impedentiometry. Adjusting for body surface area (in 1.73 m(2)) caused a significant reduction in GFR (P < 0.0001) in overweight humans (84.1 +/- 2.32 versus 109.6 +/- 3.07 mL/min/1.73 m(2)). The difference disappeared when GFR/height criteria were adopted. No difference between obese and healthy controls occurred after adjusting for lean body weight. Data for creatinine clearance paralleled those with insulin clearance; a significant reduction (P < 0.001) occurred after indexing for basal surface area, which disappeared after correction for height, as well as for lean body weight.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845829     DOI: 10.1016/s0272-6386(00)70052-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  13 in total

1.  Lean body mass normalizes the effect of obesity on renal function.

Authors:  Sarayut Janmahasatian; Stephen B Duffull; Avry Chagnac; Carl M J Kirkpatrick; Bruce Green
Journal:  Br J Clin Pharmacol       Date:  2008-02-15       Impact factor: 4.335

2.  Indexing glomerular filtration rate to body surface area: clinical consequences.

Authors:  Belén Redal-Baigorri; Knud Rasmussen; James Goya Heaf
Journal:  J Clin Lab Anal       Date:  2013-12-27       Impact factor: 2.352

Review 3.  Designing drug regimens for special intensive care unit populations.

Authors:  Brian L Erstad
Journal:  World J Crit Care Med       Date:  2015-05-04

4.  Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes.

Authors:  Adam Ogna; Valentina Forni Ogna; Murielle Bochud; Idris Guessous; Fred Paccaud; Michel Burnier; Gregoire Wuerzner
Journal:  Eur J Nutr       Date:  2015-05-14       Impact factor: 5.614

5.  Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy.

Authors:  Grégoire Wuerzner; Murielle Bochud; Vittorio Giusti; Michel Burnier
Journal:  Obes Facts       Date:  2011-06-06       Impact factor: 3.942

6.  Improving Medication Dosing in the Obese Patient.

Authors:  Brian L Erstad
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

7.  Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.

Authors:  Cyrus Ghobadi; Trevor N Johnson; Mohsen Aarabi; Lisa M Almond; Aurel Constant Allabi; Karen Rowland-Yeo; Masoud Jamei; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

8.  Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.

Authors:  B Green; M Greenwood; D Saltissi; J Westhuyzen; L Kluver; J Rowell; J Atherton
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 9.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 10.  Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.

Authors:  Vivette D D'Agati; Avry Chagnac; Aiko P J de Vries; Moshe Levi; Esteban Porrini; Michal Herman-Edelstein; Manuel Praga
Journal:  Nat Rev Nephrol       Date:  2016-06-06       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.